



Drug Coverage Policy

Effective Date02/27/2025
Coverage Policy Number.....IP0725
Policy Title.....Kebilidi

Neurology – Gene Therapy – Kebilidi

- Kebilidi® (eladocagene exuparvovec-tneq suspension for intraputaminial infusion - PTC Therapeutics)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see “Coding Information” below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

OVERVIEW

Kebilidi, an adeno-associated virus vector-based gene therapy, is indicated for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency in adult and pediatric patients.¹ The indication is approved under accelerated approval based on change from baseline in gross motor milestone achievement at 48 weeks after administration of Kebilidi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Kebilidi is given as a single-dose intraputamen infusion only.¹ The total recommended dose is 1.8×10^{11} vector genomes (0.32 mL) which is administered by four intraputamen infusions in a single stereotactic neurosurgical procedure. Kebilidi is intended to be given with an infusion pump that is able to permit infusion at a rate of 0.003 mL/minute. Two infusions are delivered in the anterior putamen and two in the posterior putamen. At each target point, the duration of the infusion is 27 minutes. Kebilidi should be administered only using an FDA-authorized cannula for intraparenchymal infusion. This gene therapy should be given in a medical center that specializes in stereotactic neurosurgery. It should be confirmed that the patient has AADC deficiency due to biallelic mutations in the dopa decarboxylase (*DDC*) gene. Of note, the safety and effectiveness of Kebilidi have not been studied in pediatric patients < 16 months of age.

Disease Overview

Aromatic L-amino acid decarboxylase deficiency is a rare genetic neurological disorder that is caused by pathogenic variants in the *DDC* gene that encodes for the AADC enzyme.²⁻⁵ AADC enzyme deficiency leads to an inability to synthesize dopamine and serotonin from their precursors. The onset of the condition is usually in early infancy. Impacted patients may experience various complex symptoms such as delays in gross motor function (head control, standing, and walking), hypotonia (weak muscle tone), and developmental and/or cognitive delays. Complications may be life-threatening.²⁻⁵ In the US, the estimated newborn at-risk population for AADC deficiency is around 1/42,000 to 1/190,000 births.⁶ The Peabody Developmental Motor Scale, Second Edition (PDMS-2) is a tool utilized to evaluate patient response.⁷ The overall PDMS-2 involves six subtests that evaluate motor abilities that develop early in life (e.g., grasping, visual-motor integration, reflexes, stationary, locomotion, and object manipulation).

Clinical Efficacy

Kebilidi was assessed for efficacy in one open-label, single-arm study that involved 13 pediatric patients (median age of 2.8 years [range 1.3 to 10.8 years]).¹ Patients had achieved skull maturity assessed by neuroimaging. Genetic confirmation of AADC deficiency was required¹ and patients also had decreased AADC enzyme activity in plasma.⁸ Patients also must have had persistent neurologic defects secondary to AADC deficiency despite standard medical therapy (e.g., dopamine agonists, monoamine oxidase [MAO] inhibitors, pyridoxine).⁸ Gross motor milestone achievement was assessed at Week 48 utilizing the PDMS-2.¹ Comparisons with patients given Kebilidi were made to an external untreated natural history cohort involving 43 pediatric patients who had severe AADC deficiency. At Week 48, assessment of gross motor milestone achievement occurred in 12 of the 13 patients treated with Kebilidi. In total, 67% of the treated patients achieved a new gross motor milestone at Week 48 (e.g., head control, sitting [with or without assistance], ability to walk backwards). In comparison with the 43 untreated patients with the severe phenotype, none of the patients experienced motor milestone achievement at last assessment at a median age of 7.2 years (range 2 to 19 years).¹ Other data are also available that describe the effects of Kebilidi in patients with AADC deficiency.²

Guidelines

Current guidelines do not address Kebilidi. A consensus guideline for the diagnosis and treatment of AADC deficiency is available from the International Working Group on Neurotransmitter Related

Disorders (2017).⁵ Many recommendations are provided. In most patients, AADC deficiency can be confirmed by genetic testing. The three main diagnostic elements for this condition include the following: 1) decreased AADC enzyme activity in plasma; 2) compound heterozygous or homozygous pathogenic variants in the *DDC* gene; and 3) examination of cerebral spinal fluid (CSF) neurotransmitter levels. Of note, CSF neurotransmitter levels that suggest a diagnosis of AADC deficiency are low levels of 5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxy 4-hydroxyphenylglycol; increased levels of 3-O-methyldopa, 3,4-dihydroxyphenylalanine, and 5-hydroxytryptophan; and normal CSF pterins. It is recommended that genetic testing be performed and at least two of the three diagnostic tests cited above be positive. First-line treatments for AADC deficiency are dopamine agonists, MAO inhibitors (e.g., tranylcypromine, selegiline), and pyridoxine. Among the dopamine agonists, non-ergot derived agents are preferred (e.g., pramipexole, ropinirole, rotigotine). Cabergoline and pergolide should not be utilized due to the high risk of fibrotic complications. Although there is limited evidence regarding clinical benefit, MAO inhibitors should be tried in patients as these agents prevent the breakdown of dopamine and serotonin. Vitamin B6 is considered a first-line treatment from a biochemical standpoint. However, dose limits should be considered due to adverse events. In addition, anticholinergic medications can be considered for management of various symptoms (e.g., autonomic symptoms).

Coverage Policy

POLICY STATEMENT

Prior Authorization is recommended for benefit coverage of Kebilidi. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Because of the specialized skills required for evaluation and diagnosis of patients treated with Kebilidi as well as the specialized training required for administration of Kebilidi, approval requires Kebilidi to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for one-time (per lifetime) as a single dose. If claims history is available, verification is required for certain criteria, as noted by **[verification in claims history required]**. For dosing criteria, verification is required by the Medical Director as noted by **[verification required]**. All reviews (approvals and denials) will be forwarded to the Medical Director for evaluation.

Documentation: Documentation is required for use of Kebilidi as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, claims records, prescription receipts, and/or other information.

Kebilidi is considered medically necessary when the following criteria are met: FDA-Approved Indication

- 1. Aromatic L-Amino Acid Decarboxylase Deficiency.** Approve a one-time (per lifetime) single dose if the patient meets ALL of the following (A, B, C, D, E, F, G, and H):
 - A)** Patient is \geq 16 months of age; AND
 - B)** Patient has achieved skull maturity as evaluated by neuroimaging **[documentation required]**; AND
 - C)** Patient has not received Kebilidi in the past **[verification in claims history required]**; AND

Note: If no claim for Kebilidi is present (or if claims history is not available), the prescribing physician confirms that the patient has not previously received Kebilidi.

- D) Patient has biallelic pathogenic variants in the dopa decarboxylase (*DDC*) gene **[documentation required]**; AND
- E) Patient has decreased aromatic L-amino acid decarboxylase (AADC) enzyme activity in plasma per current laboratory standards **[documentation required]**; AND
- F) According to the prescribing physician, the patient has continued symptoms of AADC deficiency despite use of at least one standard medication therapy; AND
Note: Examples of medications used for AADC deficiency include dopamine agonists (e.g., pramipexole, ropinirole, rotigotine), monoamine oxidase inhibitors (e.g., tranylcypromine, selegiline), pyridoxine, and other forms of vitamin B6.
- G) The medication is prescribed by a neurologist or a neurosurgeon; AND
- H) If criteria A through G are met, approve one dose of Kebilidi to provide for a one-time (per lifetime) single dose. The total recommended dose is 1.8×10^{11} vector genomes (0.32 mL) which is administered by four intraputaminaL infusions (0.08 mL each at a dose of 0.45×10^{11} vector genomes) in a single stereotactic neurosurgical procedure **[verification required]**.

Dosing. The recommended dose of Kebilidi is a one-time (per lifetime) single dose which provides a total of 1.8×10^{11} vector genomes (0.32 mL) which is administered by four intraputaminaL infusions (0.08 mL each at a dose of 0.45×10^{11} vector genomes) in a single stereotactic neurosurgical procedure.

Kebilidi for any other use is considered not medically necessary including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. **Prior Receipt of Gene Therapy.** This was an exclusion criterion in the pivotal study.

Coding Information

- 1) This list of codes may not be all-inclusive.
- 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

HCPCS Codes	Description
J3590	Unclassified biologics

References

1. Kebilidi™ suspension for intraputaminaL infusion [prescribing information]. Warren, NJ: PTC Therapeutics; November 2024.
2. Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. *Mol Ther.* 2022;30(2):509-518.
3. Blau N, Pearson TS, Kurian MA, Elsea SH. Aromatic L-Amino Acid Decarboxylase Deficiency. 2023 Oct 12 [updated 2025 Jan 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace

SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.

4. Lee HM, Mercimek-Andrews S, Horvath G, et al. A position statement on the post gene-therapy rehabilitation of aromatic l-amino acid decarboxylase deficiency in patients. *Orphanet J Rare Dis.* 2024;19:17.
5. Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. *Orphanet J Rare Dis.* 2017;12:12.
6. Himmelreich N, Bertoldi M, Alfadhel M, et al. Prevalence of DDC genotypes in patients with aromatic L-amino acid decarboxylase (AADC) deficiency and *in silico* prediction of structural protein changes. *Mol Genet Metab.* 2023;139(3):107624.
7. Folio MR, Fewell RR. Peabody Developmental Motor Scales-2 second edition. Examiner's manual. Austin, TX: Pro-ED;2000.
8. PTC Therapeutics. A study of smartflow magnetic resonance compatible ventricular cannula for administering eladocagene exuparvovec to pediatric participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 Jan 1]. Available at:
<https://www.clinicaltrials.gov/study/NCT04903288?term=eladocagene%20exuparvovec&rank=1>. NLM Identifier: NCT04903288.

Revision Details

Type of Revision	Summary of Changes	Date
New	New policy	02/27/2025

The policy effective date is in force until updated or retired.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.